Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873291 | 0.99 | PDE4B (0.44) | PDE4BPDE4DCA2LMNAMAPK14 | |
| SCHEMBL4869314 | 0.85 | PDIA6 (0.41) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL5703955 | 0.83 | P2RX4 (0.40) | PDE4BPDE4DCA2MAPK14CA1 | |
| SCHEMBL2183386 | 0.80 | PKM (0.55) | CA2CA12CA1CA9 | |
| SCHEMBL29551296 | 0.80 | PKM (0.55) | CA2CA12CA1CA9 | |
| SCHEMBL4873733 | 0.79 | PARP10 (0.53) | — | |
| SCHEMBL1622043 | 0.78 | NPY1R (0.44) | CA2LMNACA12CA1CA9 | |
| SCHEMBL8465928 | 0.77 | KMT2A (0.45) | PDE4BPDE4DCA2LMNAPDE4A | |
| SCHEMBL27368676 | 0.77 | ALDH1A1 (0.58) | PDE4BPDE4DCA2PDE4APDE4C | |
| SCHEMBL27521810 | 0.77 | PDE4A (0.60) | PDE4BPDE4DCA2LMNAMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| EP-1086076-B1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | HALE MICHAEL ROBIN (US) | 2004-05-20 | — | — | US | disclosed |
| US-6613743-B2 | Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | PDE4B 3968/4885PDE4D 3717/4885CA2 409/4885 |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | PDE4B 3968/4885PDE4D 3717/4885CA2 409/4885 |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | PDE4B 3968/4885PDE4D 3717/4885CA2 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.